Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients Wi ...
University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;University of Washington University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;Universit ...